Servier to pay GeNeuro $47m to test novel MS drug in Phase IIb
This article was originally published in Scrip
Executive Summary
Swiss biotech GeNeuro has entered into a partnership with French pharma Servier for GNbAC1, a novel investigational drug for multiple sclerosis (MS).